Facing a prostate cancer diagnosis can be a terrifying experience, but there's a beacon of hope emerging in the form of a groundbreaking drug combination that's significantly improving survival rates. Take the case of Suresh Patil, a retired bank manager from Mumbai. He noticed changes in his urination habits, a seemingly minor issue that led to a life-altering discovery. His prostate-specific antigen (PSA) test revealed a level of 16 ng/mL, far exceeding the normal limit of 4.0 ng/mL, indicating a tumor. But here's where it gets controversial: not only was it present, but it was also aggressive, carrying a high risk of mortality. However, a new therapy, backed by the latest multinational EMBARK trial, offers a promising solution.
This combination therapy has shown remarkable efficacy in a Phase 3 clinical trial for high-risk, recurring cancer. Dr. Amit Joshi, a professor at Tata Memorial Centre, highlights that this treatment is readily available, potentially leading to better survival outcomes. He strongly advocates for indication-driven screening to manage even the most aggressive forms of cancer effectively.
The innovative approach involves a dual-action strategy. The combination of leuprolide and enzalutamide attacks prostate cancer on two fronts. Leuprolide suppresses the production of the male hormone testosterone, while enzalutamide blocks the remaining testosterone from fueling cancer cells. This dual approach starves the cancer cells, which rely on testosterone to grow, thus slowing growth, potentially shrinking tumors, and delaying spread. As Dr. Kamlesh Bokil, a surgical oncologist based in Pune, points out, early detection through screening is crucial, as prostate cancer often shows no symptoms in its initial stages.
Unfortunately, despite early therapy, cancer can sometimes return. In Suresh's case, a digital rectal examination and MRI revealed a suspicious lesion, confirmed by a biopsy. While the cancer was initially confined to the prostate, it was high-risk and aggressive. After surgery and radiation, his PSA levels initially dropped but began to rise again, indicating a possible recurrence. This biochemical recurrence, often the first sign of cancer returning, can occur even without physical symptoms. Patients with this type of recurrence, where PSA levels double in less than nine months, face a high risk of metastasis.
But how does this combination therapy work in practice? In January of this year, Suresh began receiving leuprolide injections (22.5 mg every three months) and enzalutamide tablets (160 mg daily), following the EMBARK protocol. The results were promising: his PSA levels steadily decreased, reaching 0.05 ng/mL after three months and becoming undetectable within six months. After 37 weeks of treatment, his doctors stopped the medication, and he continues with regular PSA monitoring.
This outcome aligns with the findings of the EMBARK trial, published in the New England Journal of Medicine. The trial demonstrated that the combination therapy significantly extended overall survival. The combined use of these drugs improved survival rates in patients with locally advanced prostate cancer and reduced the risk of death by over 40 percent. Dr. Joshi emphasizes the importance of identifying high-risk patients after surgery and radiation.
The EMBARK trial involved nearly 1,000 patients from 17 countries with high-risk biochemical recurrence. They were randomly assigned to receive the combination of enzalutamide and leuprolide, leuprolide alone, or enzalutamide monotherapy. The results showed that the combination therapy was associated with a 40.3 percent lower rate of deaths compared to leuprolide alone (with an eight-year survival rate of 78.9 percent versus 69.5 percent).
So, why is screening so important? The American Cancer Society recommends screening for asymptomatic men starting at age 50. This involves PSA tests and digital rectal examinations, after consulting with your doctor. Those with risk factors, such as a family history of prostate cancer, should start screening at 45. For those at even higher risk (multiple first-degree relatives with early-onset prostate cancer or known genetic mutations like BRCA 1 and 2), screening should begin at 40. The International Agency for Research on Cancer projects that prostate cancer incidence in India will double to approximately 71,000 new cases per year by 2040.
What are your thoughts on this groundbreaking treatment? Do you think the benefits outweigh the potential side effects? Share your opinions in the comments below!
(Name changed to protect privacy)
